About Event
Why the IPF Summit?
The IPF field feels undoubtedly exciting and companies seem to be moving swiftly through clinical trials!
However, understanding lung pathobiology to explore the early vs late drivers of pulmonary fibrosis, using valuable preclinical models for IND-enabling and to cement translational confidence, whether to harness imaging as a secondary, exploratory endpoint throughout therapeutic development, patient selection and patient recruitment, are some of the questions running through the IPF minds and are at the centre of every conversation.
Therefore, it is vital for the community to come together in 2024 to further:
Don’t miss out on the conversations the IPF community will be having next August 2024, be in the conversations to overcome the challenges and advance the next generation of IPF drugs.
In the 2023 Agenda
Attendees heard phase 2 and 3 clinical trial updates from Bristol Myers Squibb, Pliant Therapeutics, Galecto, and Vicore Pharma and took away key lessons , while benchmarking their drug development to bring more efficacious therapeutics to patients faster.
About the Emerging Biology & Early Translational Track:
 |
Determine the importance of epithelial and endothelial cells, explore repair, regeneration, and clearing senescent cells to understand the pathobiology of pulmonary fibrosis with National Jewish Health, Genentech, and Boehringer Ingelheim | |
 |
Illuminate early-stage biomarkers for patient selection and identification for therapeutic development with Gatehouse Bio, Astrazeneca, and Pfizer | |
|
Explore novel, dynamic preclinical models to use in combination with the bleomycin model to create a compelling IND-enabling package and have translational confidence in your IPF pipeline with Genentech, Oxcia and Pieris Pharmaceuticals | |
 |
Understand cell cross talk using genomics, proteomics and RNA sequencing with Naftali Kaminski | |
|
Understanding the functional consequences of genetic abnormalities for pulmonary fibrosis and the opportunity to use genetics as a superior predictive tool with Gisli Jenkins and Harvard Medical School |
About the Late Translational
and Clinical Track:
 |
Harness imaging and use AI as endpoints in clinical trials to measure biomarkers beyond lung function with Toby Maher, Boehringer Ingelheim, and Imperial College London | |
 |
Capture interstitial lung abnormalities (ILAs) to illuminate early-stage disease and progression of pulmonary fibrosis with Harvard Medical School and Boehringer Ingelheim | |
 |
Explore using innovative biomarkers in therapeutic development for a precision medicine approach in pulmonary fibrosis with AstraZeneca, Pfizer, and University of Michigan | |
|
Assess clinical trial designs from patient selection of early- vs late-stage vs those on the standard of care, 12 week vs 52 week studies, decentralized trials, and more to design swifter and efficacious trials with Toby Maher, AstraZeneca, Vicore, Pulmonary Fibrosis Foundation and Gilead | |
|
Deliberate combination considerations to look ahead as multiple therapeutics are expected to hit the market to debate sequential therapies including MoA, modelling, administration, and trial design with AbbVie and Gilead |
Who Did You Meet?
180+ senior decision makers from C-Level executives to senior scientists from the leading pulmonary fibrosis biopharma companies will unite in Boston with the KOL academics including Toby Maher, Fernando Martinez, Naftali Kaminski, Gisli Jenkins, and many more. Individuals across the whole teams of discovery science, research, translational, biomarker, clinical, regulatory, and patient recruitment colleagues united in one room to advance efficacious pulmonary fibrosis therapeutics forward to patients.
